Gastrointestinal motility problems in patients with Parkinson's disease

Epidemiology, pathophysiology and guidelines for management

Ronald Pfeiffer, Eamonn M M Quigley

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Gastrointestinal dysfunction is a frequent feature of Parkinson's disease and may be characterised by disordered salivation, dysphagia, gastroparesis, constipation and defecatory dysfunction. Excess saliva is noted by at least 70% of patients with Parkinson's disease and is caused by decreased swallowing frequency rather than overproduction of saliva. Treatment is largely nonpharmacological, although more effective management of dysphagia may also reduce saliva accumulation. Anticholinergic drugs are best avoided. Dysphagia develops in 50% or more of individuals with Parkinson's disease and may be due to oral, pharyngeal or oesophageal factors. Behavioural techniques taught by a speech/swallowing therapist may be useful, but optimum employment of dopaminergic medications may also provide significant improvement in 30 to 40% of patients. Surgical approaches, such as cricopharyngeal myotomy, may be appropriate in selected individuals. Impaired gastric emptying may occur in Parkinson's disease and interfere with levodopa absorption in addition to producing bloating and other symptoms. Prokinetic agents, such as cisapride and domperidone, have been successfully utilised for this problem. Bowel dysfunction in Parkinson's disease has been separated into constipation, due to slowed colon transit, and defecatory dysfunction, due to discoordinated anorectal muscular function, but the two conditions often coexist. Fibre, fluid and prokinetic agents may improve constipation; unproven modalities, such as apomorphine and botulinum toxin injections, may hold the best promise for ameliorating defecatory dysfunction.

Original languageEnglish (US)
Pages (from-to)435-448
Number of pages14
JournalCNS Drugs
Volume11
Issue number6
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Gastrointestinal Motility
Parkinson Disease
Epidemiology
Guidelines
Constipation
Deglutition Disorders
Saliva
Deglutition
Cisapride
Gastroparesis
Domperidone
Salivation
Botulinum Toxins
Apomorphine
Gastric Emptying
Cholinergic Antagonists
Levodopa
Colon
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Gastrointestinal motility problems in patients with Parkinson's disease : Epidemiology, pathophysiology and guidelines for management. / Pfeiffer, Ronald; Quigley, Eamonn M M.

In: CNS Drugs, Vol. 11, No. 6, 1999, p. 435-448.

Research output: Contribution to journalArticle

@article{82591852d71c402ea1a2aabdcfa3953b,
title = "Gastrointestinal motility problems in patients with Parkinson's disease: Epidemiology, pathophysiology and guidelines for management",
abstract = "Gastrointestinal dysfunction is a frequent feature of Parkinson's disease and may be characterised by disordered salivation, dysphagia, gastroparesis, constipation and defecatory dysfunction. Excess saliva is noted by at least 70{\%} of patients with Parkinson's disease and is caused by decreased swallowing frequency rather than overproduction of saliva. Treatment is largely nonpharmacological, although more effective management of dysphagia may also reduce saliva accumulation. Anticholinergic drugs are best avoided. Dysphagia develops in 50{\%} or more of individuals with Parkinson's disease and may be due to oral, pharyngeal or oesophageal factors. Behavioural techniques taught by a speech/swallowing therapist may be useful, but optimum employment of dopaminergic medications may also provide significant improvement in 30 to 40{\%} of patients. Surgical approaches, such as cricopharyngeal myotomy, may be appropriate in selected individuals. Impaired gastric emptying may occur in Parkinson's disease and interfere with levodopa absorption in addition to producing bloating and other symptoms. Prokinetic agents, such as cisapride and domperidone, have been successfully utilised for this problem. Bowel dysfunction in Parkinson's disease has been separated into constipation, due to slowed colon transit, and defecatory dysfunction, due to discoordinated anorectal muscular function, but the two conditions often coexist. Fibre, fluid and prokinetic agents may improve constipation; unproven modalities, such as apomorphine and botulinum toxin injections, may hold the best promise for ameliorating defecatory dysfunction.",
author = "Ronald Pfeiffer and Quigley, {Eamonn M M}",
year = "1999",
doi = "10.2165/00023210-199911060-00003",
language = "English (US)",
volume = "11",
pages = "435--448",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Gastrointestinal motility problems in patients with Parkinson's disease

T2 - Epidemiology, pathophysiology and guidelines for management

AU - Pfeiffer, Ronald

AU - Quigley, Eamonn M M

PY - 1999

Y1 - 1999

N2 - Gastrointestinal dysfunction is a frequent feature of Parkinson's disease and may be characterised by disordered salivation, dysphagia, gastroparesis, constipation and defecatory dysfunction. Excess saliva is noted by at least 70% of patients with Parkinson's disease and is caused by decreased swallowing frequency rather than overproduction of saliva. Treatment is largely nonpharmacological, although more effective management of dysphagia may also reduce saliva accumulation. Anticholinergic drugs are best avoided. Dysphagia develops in 50% or more of individuals with Parkinson's disease and may be due to oral, pharyngeal or oesophageal factors. Behavioural techniques taught by a speech/swallowing therapist may be useful, but optimum employment of dopaminergic medications may also provide significant improvement in 30 to 40% of patients. Surgical approaches, such as cricopharyngeal myotomy, may be appropriate in selected individuals. Impaired gastric emptying may occur in Parkinson's disease and interfere with levodopa absorption in addition to producing bloating and other symptoms. Prokinetic agents, such as cisapride and domperidone, have been successfully utilised for this problem. Bowel dysfunction in Parkinson's disease has been separated into constipation, due to slowed colon transit, and defecatory dysfunction, due to discoordinated anorectal muscular function, but the two conditions often coexist. Fibre, fluid and prokinetic agents may improve constipation; unproven modalities, such as apomorphine and botulinum toxin injections, may hold the best promise for ameliorating defecatory dysfunction.

AB - Gastrointestinal dysfunction is a frequent feature of Parkinson's disease and may be characterised by disordered salivation, dysphagia, gastroparesis, constipation and defecatory dysfunction. Excess saliva is noted by at least 70% of patients with Parkinson's disease and is caused by decreased swallowing frequency rather than overproduction of saliva. Treatment is largely nonpharmacological, although more effective management of dysphagia may also reduce saliva accumulation. Anticholinergic drugs are best avoided. Dysphagia develops in 50% or more of individuals with Parkinson's disease and may be due to oral, pharyngeal or oesophageal factors. Behavioural techniques taught by a speech/swallowing therapist may be useful, but optimum employment of dopaminergic medications may also provide significant improvement in 30 to 40% of patients. Surgical approaches, such as cricopharyngeal myotomy, may be appropriate in selected individuals. Impaired gastric emptying may occur in Parkinson's disease and interfere with levodopa absorption in addition to producing bloating and other symptoms. Prokinetic agents, such as cisapride and domperidone, have been successfully utilised for this problem. Bowel dysfunction in Parkinson's disease has been separated into constipation, due to slowed colon transit, and defecatory dysfunction, due to discoordinated anorectal muscular function, but the two conditions often coexist. Fibre, fluid and prokinetic agents may improve constipation; unproven modalities, such as apomorphine and botulinum toxin injections, may hold the best promise for ameliorating defecatory dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0033014922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033014922&partnerID=8YFLogxK

U2 - 10.2165/00023210-199911060-00003

DO - 10.2165/00023210-199911060-00003

M3 - Article

VL - 11

SP - 435

EP - 448

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 6

ER -